DNLI

Business Context and Reporting Period

Company: Denali Therapeutics Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2017
Business Overview: Denali is an early-stage clinical biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. The company utilizes a proprietary blood-brain barrier (BBB) platform technology (Antibody Transport Vehicle and Enzyme Transport Vehicle) to deliver large molecules into the brain. As of the reporting date, the company had no approved products and no product revenue.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt as of December 31, 2017.

Material Changes vs. Prior Period

• Initial Public Offering (IPO): In December 2017, the company completed its IPO, issuing approximately 16 million shares at $18.00 per share, raising net proceeds of approximately $264.3 million. This significantly increased cash reserves from $250.9 million in 2016 to $467.0 million in 2017.
• Operating Expenses: Total operating expenses increased slightly by 3% to $90.1 million in 2017 compared to $87.4 million in 2016. This was driven by a 34% increase in General and Administrative expenses (due to public company compliance costs and headcount growth), partially offset by a 2% decrease in R&D expenses.
• R&D Expense Drivers: The decrease in R&D expenses was primarily due to the absence of a $5.3 million contingent stock consideration expense related to the Incro acquisition (recognized in 2016) and a $5.5 million upfront payment to F-star (recognized in 2016). These were partially offset by increased personnel costs and a $2.5 million milestone payment to Genentech.
• Net Loss: Net loss increased slightly by 2% to $88.2 million, consistent with the increase in operating expenses, despite higher interest income ($2.0 million in 2017 vs. $0.8 million in 2016).

Guidance, Outlook, and Risks

Outlook and Milestones:

• Clinical Progress: The company has three product candidates in Phase 1 clinical trials: DNL201 and DNL151 (LRRK2 inhibitors for Parkinson's) and DNL747 (RIPK1 inhibitor for Alzheimer's/ALS). DNL747 dosing began in March 2018.
• Collaboration with Takeda: In January 2018, Denali entered a collaboration with Takeda covering three programs (ATV:BACE1/Tau, ATV:TREM2, and an undisclosed program). This agreement included a $40 million upfront payment, a $5 million milestone, and a $110 million equity investment by Takeda (closed February 2018).
• Liquidity: Management believes existing cash and marketable securities are sufficient to fund operations through at least the next 12 months from the filing date.

Risks and Contingencies:

• Development Risk: The company has no approved products and faces significant risks regarding the success of clinical trials, regulatory approval, and the ability to commercialize products.
• Capital Requirements: The company expects to continue incurring significant losses and will require substantial additional funding to advance its pipeline. Future capital may not be available on acceptable terms.
• Intellectual Property: Success depends on obtaining and maintaining patent protection for its BBB platform and product candidates. The company relies on licenses from third parties (e.g., Genentech, F-star) which may be terminated or challenged.
• Regulatory Holds: The DNL201 program was previously subject to a partial clinical hold by the FDA, which was lifted in December 2017. Future holds remain a risk.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $467 million cash balance against the projected burn rate, considering the significant upcoming costs for advancing multiple Phase 1 and preclinical programs.
• Takeda Collaboration Terms: Review the specific milestones and cost-sharing obligations under the Takeda agreement to understand future revenue potential and liability exposure.
• Clinical Trial Status: Monitor the safety and efficacy data from the ongoing Phase 1 trials for DNL201, DNL151, and DNL747, as failure in these early stages would materially impact the company's valuation.
• License Agreements: Assess the terms of the Genentech and F-star licenses, including potential future milestone payments (up to $315 million for Genentech and significant amounts for F-star) and royalty obligations.
• Stock-Based Compensation: Note that stock-based compensation was $4.4 million in 2017 and is expected to increase as the company grows and grants new equity awards.